Not necessarily. Vaccines typically provide broader and stronger immunity than natural immunity does.
MESO-Rx
Anabolic Steroids
Can touching a barbell in the gym get you sick with the coronavirus?
- Thread starter Michael Scally MD
- Start date
I agree that vaccines work and am definitely pro- vaccines. The only thing I will dispute is the efficacy and your statement about not one death. Covid 19 now has many variants and I believe it is Moderno that has now introduced a booster. The flu vaccine is down to about 17% efficacy, This is due to the variants of flu. Same thing with Covid. Yes it is 95% effective against Covid 19 as we now know it but it is changing by the day. This will turn into the flu vaccine where there will be a new one every year.
It’s not just Russia - it’s many people from many countries including top scientists and medical professionals. Anytime someone presents opposing views - they are labeled as conspiracy theorists or it’s all RUSSIAN disinformation. That attitude only limits advanced in science. Debate is necessary for science to flourish.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine.
Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein. Serum was derived from 40 subjects in two age groups 21 days after the booster shot.
The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant.
Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. Science 2021;371:1103. http://science.sciencemag.org/content/371/6534/1103.abstract
Vaccine candidates based on spike, the glycoprotein that is essential for host cell entry by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being designed within days of its reported sequence in January 2020. All the vaccines aim to prevent disease primarily (but not exclusively) by eliciting neutralizing antibodies that block spike and therefore prevent the ability of SARS-CoV-2 to infect cells.
The 95% efficacy of the BNT162b2 messenger RNA (mRNA) vaccine (from Pfizer/BioNTech) heralded a series of results showing that eliciting neutralizing antibodies to spike strongly correlated with protection from disease in clinical trials of various vaccines. Currently, there is concern about reduced vaccine-induced immune protection to emerging variants that have mutations in the spike protein.
On page 1152 of this issue, Muik et al. (1) found reduced induction of neutralizing antibodies from BNT62b2. However, there is likely sufficient efficacy remaining to confer protection from symptomatic disease.
Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science 2021;371:1152. http://science.sciencemag.org/content/371/6534/1152.abstract
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom.
This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected.
In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2.
The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein. Serum was derived from 40 subjects in two age groups 21 days after the booster shot.
The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant.
Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. Science 2021;371:1103. http://science.sciencemag.org/content/371/6534/1103.abstract
Vaccine candidates based on spike, the glycoprotein that is essential for host cell entry by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being designed within days of its reported sequence in January 2020. All the vaccines aim to prevent disease primarily (but not exclusively) by eliciting neutralizing antibodies that block spike and therefore prevent the ability of SARS-CoV-2 to infect cells.
The 95% efficacy of the BNT162b2 messenger RNA (mRNA) vaccine (from Pfizer/BioNTech) heralded a series of results showing that eliciting neutralizing antibodies to spike strongly correlated with protection from disease in clinical trials of various vaccines. Currently, there is concern about reduced vaccine-induced immune protection to emerging variants that have mutations in the spike protein.
On page 1152 of this issue, Muik et al. (1) found reduced induction of neutralizing antibodies from BNT62b2. However, there is likely sufficient efficacy remaining to confer protection from symptomatic disease.
Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science 2021;371:1152. http://science.sciencemag.org/content/371/6534/1152.abstract
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom.
This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected.
In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2.
The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
Similar threads
